No abstract

<i>Objective:</i> To determine if the bihormonal bionic pancreas (BHBP) improves glycemic control and reduces hypoglycemia in individuals with congenital hyperinsulinism (HI) and post-pancreatectomy diabetes (PPD) compared with usual care (UC). <p><i>Methods</i>: Ten subjects with HI and PPD completed this open-label, crossover pilot study. Co-primary outcomes were mean glucose concentration and time with continuous glucose monitoring (CGM) glucose concentration <3.3 mmol/L.</p> <p><i>Results</i>: Mean (SD) CGM glucose concentration was 8.3 mmol/L (0.7) in the BHBP period vs. 9 mmol/L (1.8) in the UC period (p=0.13). Mean (SD) time with CGM glucose concentration <3.3 mmol/L was 0% (0.002) in the BHBP period vs. 1.3% (0.018) in the UC period (p=0.11). </p> <p><i>Conclusion</i>: Relative to UC, the BHBP resulted in comparable glycemic control in our population. </p>

No abstract

<p>  </p> <p><strong>Objective: </strong>We evaluated the performance of the iLet® bionic pancreas (BP) in non-Hispanic Whites (‘Whites’) and in Blacks, Hispanics, and others (‘Minorities’).</p> <p><strong>Research Design and Methods:</strong> A multicenter, randomized controlled trial evaluated glycemic management with the BP versus standard-of-care (SC) in 161 adult and 165 pediatric participants with type 1 diabetes over 13 weeks. </p> <p><strong>Results:</strong> In Whites (N=240), the mean baseline-adjusted difference in 13-week HbA1c between the BP and SC groups was -0.45% (95% CI -0.61% to -0.29% [-4.9, -6.6 to -3.1 mmol/mol]; P<0.001), while this difference among Minorities (N=84) was -0.53% (-0.83% to -0.24% [-6.0, -9.2 to -2.8 mmol/mol]; P<0.001). In Whites, the mean baseline-adjusted difference in TIR between the BP and SC groups was 10% (7 to 12%; P<0.001), while in Minorities it was 14% (10 to 18%; P<0.001). </p> <p><strong>Conclusions:</strong> The BP improves glycemic control in both Whites and Minorities and offers promise in decreasing health care disparities. </p>